{"id":46558,"date":"2022-07-26T11:01:37","date_gmt":"2022-07-26T09:01:37","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/acquired-von-willebrand-disease-avwd-treatment-market-research-report-2022-researchandmarkets-com\/"},"modified":"2022-07-26T11:01:37","modified_gmt":"2022-07-26T09:01:37","slug":"acquired-von-willebrand-disease-avwd-treatment-market-research-report-2022-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/acquired-von-willebrand-disease-avwd-treatment-market-research-report-2022-researchandmarkets-com\/","title":{"rendered":"Acquired von Willebrand Disease (AvWD) Treatment Market Research Report 2022 – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Acquired von Willebrand Disease (AvWD) Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThe acquired von willebrand disease treatment market is anticipated to grow, at a CAGR of 5.86% during the forecast period of 2022 to 2030.\n<\/p>\n

\nThis research report presents the analysis of each segment from 2020 to 2030 considering 2021 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segment are calculated for the forecast period from 2022 to 2030.\n<\/p>\n

\nDiagnosis Remains as The Largest Challenge<\/strong>\n<\/p>\n

\nAvWD screening becomes crucial in patients with onco-hematologic disorders, patients who experienced unexplained bleeding, or before undergoing any invasive procedure. The acquired von Willebrand disease prevalence represents about 1% to 5% of all von Willebrand disease. Its prevalence is higher in certain groups.\n<\/p>\n

\nFor example, it has been reported up to 20% of malignancies, and up to 100% of certain high flow states such as extracorporeal membrane oxygenation (ECMO) and metallic cardiac valves. The diagnostic complexity and milder form of AvWS without symptoms make it difficult to finalize on the actual prevalence rate of AvWD.\n<\/p>\n

\nIncreasing Support of Governments Led by Increasing Awareness of AvWS<\/strong>\n<\/p>\n

\nThe demand for the AvWD treatment market has increased as governments across the globe have become increasingly aware of the von Willebrand syndrome and its associated treatment. The treatment for this condition varies across countries.\n<\/p>\n

\nHowever, one of the significant driver impacting the market revenues is rising prevalence of bleeding disorders especially acquired bleeding disorders. Von Willebrand disease is a fairly prevalent bleeding disorder, according to the World Federation of Hemophilia. Von Willebrand disease is caused by a deficiency in the protein known as the Von Willebrand factor, which is present in the blood.\n<\/p>\n

\nDesmopressin records the highest revenues<\/strong>\n<\/p>\n

\nIn the year 2021, Desmopressin recorded the highest revenues in comparison to the other drugs. Desmopressin remains as the first line therapy for AvWD and is proven to be efficient for patients with mild symptoms.\n<\/p>\n

\nEasy accessibility of Desmopressin across the globe and availability of Desmopressin through different routes of drug administration such as injection, tablet and intranasal spray remains as the key driver for the dominance of this market segment.\n<\/p>\n

\nInjections Remained as Dominant Form Among Route of Drug Administration<\/strong>\n<\/p>\n

\nIn the year 2021, Injection as a mode of AvWD drug administration dominated the market segment with revenues of about $ 20,880 thousand. Major AvWD treatment drugs are administered through injections and infusions.\n<\/p>\n

\nPrimary drug Desmopressin is widely administered through injections, similarly replacement therapies are also administered through this route. Injections respond very quickly during emergency and are very effective mode of drug administration. Therefore, the market is also expected to grow at the fastest pace during the forecast period.\n<\/p>\n

\nNorth America Dominates In terms of Market Revenues<\/strong>\n<\/p>\n

\nNorth America was observed as the largest market for AvWD treatment in 2021. North America dominated the market due to its aging population, supportive government policies, high awareness associated with hemophilia and types in people, and developed healthcare infrastructure.\n<\/p>\n

\nAsia Pacific was observed as the attractive market for AvWS treatment due to its emerging healthcare infrastructure, high disposable income, transforming government policies specific to orphan diseases diagnosis and treatment, and rising public awareness associated with healthcare insurance and disease diagnosis.\n<\/p>\n

\nThe key players in the acquired AvWS treatment market are Novo Nordisk A\/S, Genentech, Inc., F. Hoffman-La Roche AG, Sanofi SA, and others.\n<\/p>\n

\nKey questions answered in this report<\/strong>\n<\/p>\n